Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab

The goal of this Phase 1b clinical trial is to evaluate the safety and efficacy of cryoablation and hepatic arterial administration of SD-101 in participants with advanced hepatocellular carcinoma. After this procedure, participants will be treated with tremelimumab and durvalumab every 4 weeks (STRIDE regimen).

Trial Details

NCT ID

NCT06710223

Phase

PHASE1

Sponsor

University of California, San Diego

Status

RECRUITING

Cancer Type

Hepatocellular Carcinoma (HCC) Liver Cancer

Interventions

SD-101
Cryotherapy
Tremelimumab
Durvalumab

Locations (sample)

San Diego, California, United States|32.71571,-117.16472

Key Eligibility Criteria

Willing and able to provide written informed consent prior to performance of any study- specific procedures.
Age ≥ 18 years.
Locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC) with diagnosis confirmed by histology/cytology or clinically by A…
For cirrhotic participants with no histological confirmation of diagnosis, clinical confirmation is required per AASLD criteria.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →